Bis(methyl)gliotoxin proves to be a more stable and reliable marker for invasive aspergillosis than gliotoxin and suitable for use in diagnosis

Instituto de Carboquímica ICB-CSIC, Zaragoza, Spain.
Diagnostic microbiology and infectious disease (Impact Factor: 2.46). 04/2012; 73(1):57-64. DOI: 10.1016/j.diagmicrobio.2012.01.012
Source: PubMed


The virulence factor gliotoxin (GT) and its inactive derivative, bis(methylthio)gliotoxin (bmGT), are produced by pathogens of the genus Aspergillus. Here we report the detection of GT and bmGT in serum of humans at risk of invasive aspergillosis (IA) as well as in cultures of fungal isolates derived from patients with proven infection with A. fumigatus. Although both compounds are readily recoverable from spiked human serum or plasma, only bmGT is retained in whole blood, indicating that bmGT may be the better marker for in vivo detection. Accordingly, bmGT was found more frequently than GT in samples from patients at risk of IA and incultures of clinical isolates of A. fumigatus. In some cases, bmGT was detected before mycologic evidence ofinfection was gained. Importantly, neither GT nor bmGT was found in serum from healthy donors or from neutropenic patients without any sign of infection. Thus, bmGT presence might provide a more reliable indicator of A. fumigatus infections than GT. Due to its simplicity and sensitivity, a diagnostic technology based on this test could be easily adopted in clinical laboratories to help in the diagnosis of this often fatal fungal infection.

Download full-text


Available from: Jacques Meis
  • Source
    • "Additionally, these mutants show reduced virulence in non-neutropenic murine models but not neutropenic models [6], [18]–[20]. This toxin and/or its derivatives are also considered for use for diagnosis of IA [21], [22]. Aside from gliZ, no other transcription factors have been described to regulate the gli cluster. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Dimeric basic leucine zipper (bZIP) proteins are conserved transcriptional enhancers found in all eukaryotes. A recently reported and novel function for bZIPs is association of these proteins with secondary metabolite production in filamentous fungi. In particular a Yap-like bZIP termed RsmA ( r estorer of s econdary m etabolism A) was identified in Aspergillus nidulans that positively regulates the carcinogen sterigmatocystin. To assess for conserved function for RsmA, we examined a role of this protein in secondary metabolism in the pathogen A. fumigatus. RsmA was found to positively regulate gliotoxin where overexpression (OE) of rsmA led to 2–100 fold increases of twelve gli cluster metabolites in culture medium including the newly identified gli metabolite cyclo(L-Phe-L-Ser). Lungs from both wild type and OErsmA infected mice co
    Full-text · Article · May 2013 · PLoS ONE
  • [Show abstract] [Hide abstract]
    ABSTRACT: Invasive aspergillosis (IA) is a life-threatening complication of haematological malignancy and haematopoietic stem cell transplantation caused by the ubiquitous fungus Aspergillus. Current diagnosis of IA is multifaceted relying on data from clinical, radiological, and microbiological sources. The detection of Aspergillus biomarkers provides strategies both to pre-empt and to exclude disease, but the choice of biomarker assays is limited, requiring specialist equipment and training. This review examines recent advances in the accurate diagnosis of IA through the development of an Aspergillus lateral-flow device (LFD) incorporating a monoclonal antibody, JF5, which detects an antigenic marker of active infection. Recent trials using bronchoalveolar lavage fluids and serum samples from humans and from animal models of disease, have demonstrated the utility of the LFD as a rapid and user-friendly adjunct test for the quick and accurate diagnosis of pulmonary infections.
    No preview · Article · Sep 2013 · Current Fungal Infection Reports
  • [Show abstract] [Hide abstract]
    ABSTRACT: Invasive fungal infections are a major cause of morbidity and mortality in immunosuppressed patients with fatality rates ranging from 30 % to 80 % in neutropenic patients. This results at least partly in difficulties obtaining a reliable and early diagnosis, followed by the fact that clinical symptoms are unspecific and of very limited use. Conventional methods may be difficult and are often delayed. Serological tests like the galactomannan enzyme immunoassay are presently most promising for diagnosing invasive aspergillosis, however, sensitivity and specificity varies within the studies. This review reflects the current situation of diagnosing invasive fungal infections with a special focus on how to best diagnose Aspergillus-related infections (e.g., culture, microscopy, imaging techniques, CT-guided biopsies). Promising molecular techniques under development will be discussed and their potential for routine diagnostic applications (e.g. lateral flow device, polymerase chain reaction [PCR]-based assays, rolling circle amplification [RCA], loop-mediated amplification [LAMP], nucleic acid sequence-based amplification [KASBA]). A summary is given on commercial assays (e.g., Platelia Aspergillus®, Fungitell®, in situ hybridization, immunohistochemisty) and their purposes as screening tools and/or diagnostic tools. This review gives a future outlook on how to best diagnose Aspergillus infections.
    No preview · Article · Dec 2012 · Current pharmaceutical design
Show more